Foundation Medicine, Inc.

  • Booth: 2005a

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. We're excited to share our work in advancing precision medicine in oncology at ASCO 2021. Learn More >>

Brands: https://i.ibb.co/Y2TV7MX/ASCO2021-Virtual-Exhibit-Hall-Header-Commercial-V2.png


 Show Specials

  • <iframe width="560" height="315" src="https://www.youtube.com/embed/2qvTIcrwe4w" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

 Press Releases

  • https://www.foundationmedicine.com/test/foundationone-heme?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • https://www.foundationmedicine.com/resource/why-comprehensive-genomic-profiling?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • https://www.foundationmedicine.com/blog/companion-diagnostics-explained-their-critical-role-in-cancer-care-and-our-latest-approvals?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • https://www.foundationmedicine.com/test/foundationone-cdx?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • https://www.foundationmedicine.com/test/foundationone-liquid-cdx?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • (Apr 30, 2021)
    https://www.foundationmedicine.com/info/provider-overview?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • https://www.foundationmedicine.com/info/biopharma-overview?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021
  • (Apr 30, 2021)
    https://www.foundationmedicine.com/service/genomic-data-solutions?utm_source=virtual_exhibit&utm_medium=referral&utm_campaign=ASCO2021

 Products

  • 3. Genomic Data Solutions
    Foundation Medicine provides genomic data solutions to accelerate and de-risk precision oncology development with our biopharma partners. Biopharma companies can extract key insights from our database to; identify or validate novel targets and pathways, discover and refine biomarkers to stratify patients, inform trial design and indication selection, and calculate prevalence to understand commercial potential and strategy. Learn more at foundationmedicine.com....

  • 1. One Proven Portfolio. That's Our Foundation.
    Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options—giving physicians and patients powerful actionable insights for navigating cancer care. FDA-approved tissue AND blood-based testing is available for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. There is also the option to add on immunohistochemistry (IHC) testing....

  • 2. Why Comprehensive Genomic Profiling?
    Comprehensive genomic profiling identifies more types of alterations from a single test. A single comprehensive genomic profiling (CGP) test can analyze more than 300 genes across the four main classes of alterations: base substitutions, insertions and deletions, copy number alterations (CNAs), and rearrangements or fusions. This type of molecular testing produces comprehensive patient reports with a broad and deep assessment of possible underlying oncogenic drivers. Learn more at foundationmedicine.com....